Duvyzat, or givinostat, targets pathogenic processes in the body to reduce inflammation and muscle loss. The twice-daily oral medication is indicated for children 6 and older with the rare neuromuscular condition.
In a phase 3 clinical trial, patients treated with Duvyzat demonstrated better physical function and took less time to climb four stairs compared to a placebo group, marking a statistically significant difference.
The drug’s prescribing information includes a warning for clinicians, advising them to evaluate patients’ platelet counts and triglycerides before prescribing.
The approval comes after the FDA granted the drug priority review, orphan drug and rare pediatric disease designations.
Learn more here.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
